Intravenous nivolumab combined with neurosurgical resection and intracerebral ipilimumab monotherapy or ipilimumab+nivolumab showed promising results in patients with IDH-wild-type GBM, as increased p-ERK was correlated with prolonged survival rates [247]. Here, IDH2 is linked to glioblastoma.